Physician profile
Patricia A Dettenmeier
NPI 1861460180
$8,573.66
in general payments reported to CMS, 2019-2025
20 companies · $1,437 in 2025
The $1,437 reported for 2025 was more than what 97% of Critical Care Medicine (Registered Nurse) providers received nationally (typical 2025 total: $51.32).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $163 · 2022: $1,764 · 2023: $2,662 · 2024: $2,547 · 2025: $1,437.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,372 · Long Term Medical Supply Or Device Loan: $1,986 · Education: $287.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,372.44 |
| Long Term Medical Supply Or Device Loan | $1,986.04 |
| Education | $287.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $3,014.15 | 2022-2024 | (8269) Dreamstation Cpap |
| Harmony Biosciences LLC | $995.36 | 2021-2025 | Wakix |
| Glaxosmithkline, LLC. | $961.01 | 2021-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Regeneron Healthcare Solutions, INC. | $871.63 | 2023-2025 | Dupixent |
| Genzyme Corporation | $503.30 | 2022-2025 | |
| Abbvie INC. | $367.20 | 2022-2024 | |
| Avadel Cns Pharmaceuticals, LLC | $365.25 | 2024-2025 | Lumryz |
| Jazz Pharmaceuticals INC. | $289.66 | 2021-2025 | |
| Inspire Medical Systems, INC. | $248.54 | 2023-2025 | Inspire |
| Mallinckrodt Hospital Products INC. | $129.51 | 2023 | Terlivaz |
| Amgen INC. | $128.84 | 2025 | |
| Neurocrine Biosciences, INC. | $125.15 | 2023 | Ongentys |
| Edwards Lifesciences Corporation | $124.29 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $122.78 | 2025 | Xifaxan |
| Astrazeneca Pharmaceuticals Lp | $116.06 | 2024 | Airsupra |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $86.25 | 2023-2025 | Sunosi |
| Merck Sharp & Dohme LLC | $65.56 | 2022-2023 | Belsomra |
| Actelion Pharmaceuticals US, INC. | $26.52 | 2024 | Uptravi, Opsumit |
| Fisher & Paykel Healthcare INC | $17.93 | 2023 | Fisher & Paykel Healthcare |
| Idorsia Pharmaceuticals US INC | $14.67 | 2025 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patricia Dettenmeier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.